5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
Briakinumab showed no clear difference in failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) compared with placebo (low certainty).
Ustekinumab leads to lower failure to induce clinical response CDAI (≥100 point reduction) compared with placebo (high certainty).
Ustekinumab leads to lower failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100… compared with placebo (high certainty).
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Ustekinumab showed no clear difference in withdrawals due to adverse event compared with placebo (low certainty).
Briakinumab may leads to lower failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point… compared with placebo (low certainty).
Briakinumab probably leads to lower failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100… compared with placebo (moderate certainty).
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
Briakinumab showed no clear difference in withdrawals due to adverse event** (Pannaccione 2010) compared with placebo (low certainty).
Ustekinumab leads to lower failure to induce clinical remission CDAI (≤ 150) compared with placebo (high certainty).
Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).